BR112019001153A2 - agonista s1p1 e aplicação do mesmo - Google Patents
agonista s1p1 e aplicação do mesmoInfo
- Publication number
- BR112019001153A2 BR112019001153A2 BR112019001153-6A BR112019001153A BR112019001153A2 BR 112019001153 A2 BR112019001153 A2 BR 112019001153A2 BR 112019001153 A BR112019001153 A BR 112019001153A BR 112019001153 A2 BR112019001153 A2 BR 112019001153A2
- Authority
- BR
- Brazil
- Prior art keywords
- application
- agonist
- relates
- sphingosine
- tautomer
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 229940121846 Sphingosine 1-phosphate receptor agonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/58—[b]- or [c]-condensed
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
a presente invenção refere-se a uma classe de compostos tricíclico e uma aplicação dos mesmos como um agonista receptor tipo 1 de 1-fosfato de esfingosina (s1p1). a invenção refere-se especificamen-te a um composto representado pela fórmula (ii), e um tautômero e sal farmaceuticamente aceitável do mesmo.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610583286 | 2016-07-22 | ||
CN201610583286.X | 2016-07-22 | ||
PCT/CN2017/093808 WO2018014862A1 (zh) | 2016-07-22 | 2017-07-21 | S1p1激动剂及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112019001153A2 true BR112019001153A2 (pt) | 2019-04-30 |
Family
ID=60991955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112019001153-6A BR112019001153A2 (pt) | 2016-07-22 | 2017-07-21 | agonista s1p1 e aplicação do mesmo |
Country Status (11)
Country | Link |
---|---|
US (1) | US11192886B2 (pt) |
EP (1) | EP3492465B1 (pt) |
JP (1) | JP6883882B2 (pt) |
KR (1) | KR102481328B1 (pt) |
CN (1) | CN109661391B (pt) |
BR (1) | BR112019001153A2 (pt) |
CA (1) | CA3034796A1 (pt) |
ES (1) | ES2877686T3 (pt) |
RU (1) | RU2754845C2 (pt) |
WO (1) | WO2018014862A1 (pt) |
ZA (1) | ZA201901089B (pt) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109563144B (zh) | 2016-06-01 | 2023-03-28 | 雅斯娜 | 化合物 |
EP3741755A4 (en) * | 2018-01-18 | 2021-09-01 | Shijiazhuang Sagacity New Drug Development Company, Ltd. | CRYSTALLINE AND SALINE FORMS OF TRICYCLIC COMPOUNDS AND THEIR PREPARATION PROCESS |
KR102333564B1 (ko) * | 2019-11-28 | 2021-12-01 | 동방에프티엘(주) | 광학 활성 다이아민 유도체 및 티아졸 유도체의 생산을 위한 새로운 합성경로 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JO2701B1 (en) * | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
US8524917B2 (en) * | 2007-01-11 | 2013-09-03 | Allergan, Inc. | 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity |
KR20090115953A (ko) * | 2007-03-06 | 2009-11-10 | 노파르티스 아게 | 염증성 또는 알레르기성 상태의 치료에 적합한 바이시클릭 유기 화합물 |
EP2210890A1 (en) * | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
WO2011005290A1 (en) | 2009-06-23 | 2011-01-13 | Arena Pharmaceuticals, Inc. | Disubstituted oxadiazole derivatives useful in the treatment of autoimmune and inflammatory disorders |
PT2498610T (pt) * | 2009-11-13 | 2018-06-19 | Celgene Int Ii Sarl | Moduladores seletivos de recetor de esfingosina 1 fosfato e métodos de síntese quiral |
MY160907A (en) * | 2009-11-13 | 2017-03-31 | Receptos Inc | Sphingosine 1 phosphate receptor modulators and methods of chiral synthesis |
MX2012006962A (es) | 2009-12-17 | 2012-07-17 | Merck Patent Gmbh | Inhibidores de la esfingosina quinasa. |
CN103298807A (zh) * | 2010-11-03 | 2013-09-11 | 百时美施贵宝公司 | 作为用于治疗自身免疫性疾病和血管疾病的s1p1激动剂的杂环化合物 |
AU2011332196A1 (en) | 2010-11-24 | 2013-07-11 | Allergan, Inc. | Indole derivatives as modulators of S1P receptors |
JP5918256B2 (ja) * | 2010-12-14 | 2016-05-18 | シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト | ストリゴラクタム誘導体および植物成長調節剤としてのこれらの使用 |
ES2758841T3 (es) * | 2011-05-13 | 2020-05-06 | Celgene Int Ii Sarl | Moduladores heterocíclicos selectivos del receptor de la esfingosina-1-fosfato |
GB201121803D0 (en) * | 2011-12-16 | 2012-02-01 | Syngenta Participations Ag | Plant growth regulating compounds |
JP6294359B2 (ja) * | 2013-02-20 | 2018-03-14 | エルジー・ケム・リミテッド | スフィンゴシン−1−リン酸受容体アゴニスト、その製造方法及びそれらを活性成分として含有する医薬組成物 |
-
2017
- 2017-07-21 ES ES17830496T patent/ES2877686T3/es active Active
- 2017-07-21 BR BR112019001153-6A patent/BR112019001153A2/pt active Search and Examination
- 2017-07-21 WO PCT/CN2017/093808 patent/WO2018014862A1/zh unknown
- 2017-07-21 EP EP17830496.0A patent/EP3492465B1/en active Active
- 2017-07-21 RU RU2019104953A patent/RU2754845C2/ru active
- 2017-07-21 US US16/319,491 patent/US11192886B2/en active Active
- 2017-07-21 CA CA3034796A patent/CA3034796A1/en active Pending
- 2017-07-21 KR KR1020197005385A patent/KR102481328B1/ko active IP Right Grant
- 2017-07-21 JP JP2019524500A patent/JP6883882B2/ja active Active
- 2017-07-21 CN CN201780044927.7A patent/CN109661391B/zh active Active
-
2019
- 2019-02-20 ZA ZA2019/01089A patent/ZA201901089B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3034796A1 (en) | 2018-01-25 |
ZA201901089B (en) | 2022-04-28 |
ES2877686T3 (es) | 2021-11-17 |
CN109661391A (zh) | 2019-04-19 |
KR20190029729A (ko) | 2019-03-20 |
JP6883882B2 (ja) | 2021-06-09 |
RU2019104953A (ru) | 2020-08-24 |
KR102481328B1 (ko) | 2022-12-26 |
JP2019522059A (ja) | 2019-08-08 |
EP3492465B1 (en) | 2021-03-24 |
EP3492465A4 (en) | 2020-03-04 |
RU2019104953A3 (pt) | 2020-08-24 |
US11192886B2 (en) | 2021-12-07 |
EP3492465A1 (en) | 2019-06-05 |
RU2754845C2 (ru) | 2021-09-08 |
CN109661391B (zh) | 2022-04-19 |
US20210300908A1 (en) | 2021-09-30 |
WO2018014862A1 (zh) | 2018-01-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CU20210009A7 (es) | Compuestos derivados de tieno pirrolo-triazina acetamida sustituida como inhibidores de la actividad inflamatoria de la proteína receptora tipo nod 3 (nlrp3) | |
PH12016502382A1 (en) | Substituted indazole compounds as irak4 inhibitors | |
CY1123059T1 (el) | Αναστολη του διαυλου ιοντων παροδικου δυναμικου του υποδοχεα α1 | |
GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
GT201500334A (es) | Compuestos de 3,4- dihidroisoquinolin-2-(1h)-ilo | |
EA201890899A1 (ru) | Модуляторы фарнезоидного x-рецептора | |
EA201792515A1 (ru) | ЗАМЕЩЕННЫЕ СОЕДИНЕНИЯ ТЕТРАГИДРОХИНОЛИНОНА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕТИНОИДНЫХ ОРФАНОВЫХ РЕЦЕПТОРОВ ГАММА (RORγ) | |
NZ713589A (en) | Tamoxifen derivatives for treatment of neoplastic diseases, especially with high her2 protein level | |
EA202090368A1 (ru) | Соединения-ингибиторы рецептора лизофосфатидной кислоты 1 (lpar1) | |
MX2015011913A (es) | Moduladores de acido oxabiciclo[2.2.2] gpr120. | |
MA40302A1 (fr) | Dérivés de carbazole | |
TN2018000020A1 (en) | Colony stimulating factor-1 receptor (csf-1r) inhibitors. | |
BR112016024936A2 (pt) | moduladores de gpr40 à base de pirrolidina para tratamento de doenças como diabetes | |
MX2015011932A (es) | Moduladores de gpr120 de acido biciclo[2.2.2]. | |
MA39335A1 (fr) | Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone | |
MX2016010973A (es) | Compuestos de aminocarbonilcarbamato. | |
MX2022000945A (es) | Composicion para incrementar la expresion de pgc-1alfa. | |
BR112019001153A2 (pt) | agonista s1p1 e aplicação do mesmo | |
MX2015011375A (es) | Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1]. | |
CL2020000376A1 (es) | Compuesto pentacíclico. | |
BR112018000513A2 (pt) | antagonistas de receptor de cgrp | |
MY185971A (en) | Pyranodipyridine compound | |
BR112019001447A2 (pt) | método de produção para composto pirazol-amida | |
BR112018012325A2 (pt) | métodos para a preparação de 5,6-di-hidro-6-fenilbenzo[f]isoquinolin-2-amina substituída | |
BR112018075817A2 (pt) | composto de fórmula (i), medicamento e composição farmacêutica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
B25A | Requested transfer of rights approved |
Owner name: MEDSHINE DISCOVERY INC. (CN) |
|
B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |